Twain therapeutics technology is based on antibody based IL-2 receptor agonists.

Twain therapeutics technology is based on antibody based IL-2 receptor agonists.​

Our Strategy

The Founders have spent many years developing Twain’s IL 2 technology, initially in Singapore’s A*Star institutes and more fully with Tessa Therapeutics.

To provide the resources and focus required to move this technology into the clinic, the Founders, together with Tessa Therapeutics and A*Star have decided to join forces to develop the IP/technology through IND enabling studies and into early-stage clinical trials.

Twain Therapeutics is also seeking partnerships with established antibody development companies in order to effect this clinical development strategy.